𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Deregulation of cofactor of BRCA1 expression in breast cancer cells

✍ Scribed by Jianlong Sun; Gareth Watkins; Ashley L. Blair; Christopher Moskaluk; Sagar Ghosh; Wen G. Jiang; Rong Li

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
311 KB
Volume
103
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Cofactor of BRCA1 (COBRA1) is an integral component of the human negative elongation factor (NELF), a four‐subunit protein complex that inhibits transcription elongation. Previous in vivo work indicates that COBRA1 and the rest of the NELF complex repress estrogen‐dependent transcription and the growth of breast cancer cells. In light of the COBRA1 function in breast cancer‐related gene expression, we sought to examine regulation of COBRA1 expression in both established breast cancer cell lines and breast carcinoma tissues. We found that COBRA1 expression was inversely correlated with breast cancer progression, as tumor samples of patients who had distant metastasis and local recurrence expressed very low levels of COBRA1 mRNA when compared to those who were disease free for over 10 years (P = 0.0065 and 0.0081, respectively). Using both breast and prostate cancer cell lines, we also explored the possible mechanisms by which COBRA1 expression is regulated. Our results indicate that the protein abundance of COBRA1 and the other NELF subunits are mutually influenced in a tightly coordinated fashion. Small interfering RNA (siRNA) that targeted at one NELF subunit dampened the protein levels of all four subunits. Conversely, ectopic expression of COBRA1 in the knockdown cells partially rescues the co‐depletion of the NELF subunits. In addition, our study suggests that a post‐transcriptional, proteasome‐independent mechanism is involved in the interdependent regulation of the NELF abundance. Furthermore, a lack of COBRA1 expression in breast carcinoma may serve as a useful indicator for poor prognosis. J. Cell. Biochem. 103: 1798–1807, 2008. © 2007 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

BRCA1 modulates malignant cell behavior,
BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells
✍ Moltira Promkan; Guangming Liu; Pimpicha Patmasiriwat; Subhas Chakrabarty 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 483 KB

## Abstract BRCA1 is a multifunctional tumor‐suppressive protein. Many functional aspects of BRCA1 are not fully understood. We used a shRNA approach to probe the function of BRCA1 in human breast cancer cells. Knocking down BRCA1 expression by shRNA in the wild‐type BRCA1 human breast cancer MCF‐7

Electromagnetic fields alter the express
Electromagnetic fields alter the expression of estrogen receptor cofactors in breast cancer cells
✍ Rainer Girgert; Carsten Gründker; Günter Emons; Volker Hanf 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

## Abstract Breast cancer is the most common malignancy of women in Western societies. The increasing exposure to electromagnetic fields has been suspected to contribute to the rising incidence of breast cancer in industrialized countries. The majority of breast tumors is treated with the partial a

BRCA1 expression levels predict distant
BRCA1 expression levels predict distant metastasis of sporadic breast cancers
✍ Liam T. Seery; Janice M. Knowlden; Julia M.W. Gee; John F.R. Robertson; Francis 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 141 KB 👁 2 views

The role of BRCA1 in progression of sporadic breast cancers has to date been equivocal, although preliminary studies on small numbers of samples have suggested an association between expression levels of this gene and acquisition of an invasive phenotype. We have further reasoned that loss of oestro

Preferential allelic expression can lead
Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers
✍ Hilmi Özçelik; Minh D. To; Jean Couture; Shelley B. Bull; Irene L. Andrulis 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 101 KB 👁 2 views

BRCA1 is considered to be a tumor-suppressor gene, yet mutations in this gene are uncommon in sporadic breast tumors. We investigated whether mechanisms other than DNA mutations that affect the coding region might be involved in breast carcinogenesis. Since loss of expression of the BRCA1 gene would

Clinical management of BRCA1- and BRCA2-
Clinical management of BRCA1- and BRCA2-associated breast cancer
✍ Stephen E. Karp 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

The recent discovery of the breast cancer-associated genes BRCA1 and BRCA2 has changed the clinical care provided to women at high risk of breast cancer. We will review what is currently known about the clinical management of patients who bear (or are suspected of bearing) mutations in either of the